Shelby Barnett

ABSTRACT Background HTL0039732 (HTL) is a novel E-type prostanoid receptor 4 (EP4) antagonist for the treatment of advanced solid tumors. An analytical method was developed to facilitate the analysis of patient samples as part of an ongoing Phase I/IIa clinical trial. Methods and results A LC-MS/MS method for quantifying HTL in human plasma was developed and validated per regulatory guidelines. The assay was selective, with a 2 ng/mL detection limit observed.

High up in the beautiful Appalachian Mountains, where morning mist swirls playfully among the ancient trees, there lived a young black bear named Bramble. Bramble was a curious little bear, always eager to learn about the world beyond his cozy spot in the laurel thicket. One sunny spring morning, Bramble woke up to a delightful new scent wafting through the air — sweet and tangy, like something special waiting to be discovered.

What is already known about this subject Mitoxantrone pharmacokinetic data in children are sparse, with limited clinical pharmacology information available to support evidence-based dosing guidance. Chemotherapy dose reductions commonly applied to infants are supported by limited evidence and can lead to reduced drug exposure compared to standard dosing. What this study adds This study improves understanding of mitoxantrone pharmacokinetics in children with acute myeloid leukaemia.